← Back to Search

Glucagon-like peptide-1 receptor agonist

semaglutide 2.4 mg for Obesity

Phase 3
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at end of treatment (week 68)
Awards & highlights

Summary

This trial will test if semaglutide injections can help people with knee pain by reducing their weight and knee pain. Participants will be randomly given either semaglutide or another treatment. The study will last for an extended period and include regular check-ups. Semaglutide is used for weight loss and type 2 diabetes treatment, showing significant efficacy in weight reduction.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at end of treatment (week 68)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at end of treatment (week 68) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score
Percentage Change in Body Weight
Secondary study objectives
Amount of Allowed Rescue Analgesics Used During Wash Out
Change in Pain Intensity (Numerical Rating Scale [NRS])
Change in SF-36 Bodily Pain Score
+20 more

Side effects data

From 2023 Phase 3 trial • 407 Patients • NCT05064735
22%
Nausea
19%
COVID-19
12%
Constipation
8%
Diarrhoea
8%
Vomiting
6%
Headache
4%
Upper respiratory tract infection
3%
Arthralgia
1%
Cholecystitis acute
1%
Breast cancer metastatic
1%
Prostate cancer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Semaglutide 2.4 mg

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: semaglutide 2.4 mgExperimental Treatment1 Intervention
Participants will receive semaglutide subcutaneous (s.c) 2.4 mg once-weekly as adjunct to a reduced-calorie diet and increased physical activity
Group II: semaglutide 2.4 mg (placebo)Placebo Group1 Intervention
Participants will receive semaglutide subcutaneous (s.c) placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
semaglutide 2.4 mg
2021
Completed Phase 3
~410

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,541 Previous Clinical Trials
2,440,663 Total Patients Enrolled
151 Trials studying Obesity
142,955 Patients Enrolled for Obesity
Clinical Transparency (Dept. 2834)Study DirectorNovo Nordisk A/S
3 Previous Clinical Trials
2,434 Total Patients Enrolled

Media Library

Semaglutide (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05064735 — Phase 3
Obesity Research Study Groups: semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Obesity Clinical Trial 2023: Semaglutide Highlights & Side Effects. Trial Name: NCT05064735 — Phase 3
Semaglutide (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05064735 — Phase 3
Obesity Patient Testimony for trial: Trial Name: NCT05064735 — Phase 3
~104 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top